Celon Pharma S.A.

Board/Management Information • Feb 14, 2025

The Management Board of Celon Pharma S.A. (the "Issuer")informs that, as a result of a review of the efficiency of the Issuer'sbusiness processes, on February 14, 2025, it adopted a resolution on theimplementation of the Issuer's new organisational regulations,whereunder three basic organisational units have been established: (i)the Shared Services Centre (the "Holding Business_quot;); (ii)Celon Pharma Speciality Pharmaceuticals_#160;(the"Generic Business"); and (iii) Celon Pharma InnovationPharmaceuticals (the "Innovation Business"). Each of theorganisational units constitutes a functionally, organisationally andfinancially separate organised part of the Issuer's enterprise.Theregulations come into effect on the day the resolution is adopted.

The purpose of establishing individual organisationalunits is to increase the efficiency of the Issuer's day-to-dayoperations and improve the management of individual areas of itsactivity and, in the long term, to increase the Issuer's competitivenessthrough the creation of competence centres in the areas of activityassigned to individual organisational units. This will ultimately makeit possible to make the further development of the Generic Business andthe Innovative Business independent, with the Holding Businesscontinuing to support both of these areas.

As part of the next stage, it is planned to carry outa demerger by separation, by separating the Issuer and transferring theGeneric Business and the Innovation Business to separate companies, ofwhich the Issuer will be the sole shareholder. The Issuer will act as aholding company and a shared services centre for the entities in theIssuer's group. As regards the Issuer's key stakeholders, i.e. theIssuer's employees and contracting parties, the separation of theGeneric Business and the Innovative Business will only mean certainformal changes (e.g. a change of the parties to the agreements linkingthem) and will not in any way affect the timeliness or the extent of thefulfilment of the Issuer's obligations. The planned separation of theGeneric Business and the Innovative Business will also not affect therights of the Issuer's shareholders.